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Abstract
The role of the European Centre for Disease Prevention and Control (ECDC) is to strengthen the capacity of the European Union (EU)
Member States to protect human health through the prevention and control of infectious diseases. The main objective of the programme on
vaccine-preventable diseases and invasive bacterial infections (VPD) is to provide robust evidence and high-quality technical support to the
EU Member States to help them in their efforts to prevent and control VPD. Since the establishment of ECDC, several existing VPD
surveillance networks have been transferred to ECDC, namely EU-IBIS, DIPNET and EUVAC. In addition to surveillance of diseases, ECDC
is collecting information and monitoring other parameters that are of crucial importance for a well-functioning immunization system,
including vaccination coverage. The VPD programme also provides independent scientiﬁc opinions in the area of immunization and initiates
and coordinates scientiﬁc studies in the area of vaccination to answer speciﬁc questions of public health importance, including risk
perception and analysis of behaviour in different population groups. One of the overall ECDC priorities over recent years is the Centre’s
involvement in measles elimination. The ‘Message’ tool and the ‘Measles Atlas’ are examples of work aiming at supporting the efforts of
Member States in the elimination phase.
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The overall role of the European Centre for Disease Prevention
and Control (ECDC) is to strengthen the capacity of the
European Community and the European Union (EU) Member
States to protect human health through the prevention and
control of infectious disease [1]. ECDC does this through
bringing together the tasks and the responsibilities of the
Member States, the EU Institutions and other international
organizations. The Programme on vaccine-preventable diseases
and invasive bacterial infections (VPD) is one of seven disease
programmes operated by ECDC [2]. The main objective of this
programme is to provide robust evidence and high-quality
technical support to the EUMember States to help them in their
efforts to prevent and control VPD [3]. The programme covers
diphtheria, invasive infections with Haemophilus inﬂuenzae,
measles, invasive meningococcal disease, mumps, pertussis,
invasive pneumococcal disease, poliomyelitis, rubella, tetanus
and varicella. Like all the other ECDC disease programmes, it is
active in various areas including surveillance, scientiﬁc advice,
epidemic intelligence and response, scientiﬁc studies, interac-
tions with external stakeholders, public health training and
health communication. We will cover these various ﬁelds of the
programme’s activity in the rest of the paper.
ECDC is the hub of European communicable disease
surveillance, working on integration of molecular surveillance
into its main surveillance activities. ECDC runs the epidemi-
ological networks, funds the laboratory networks, is in charge
of data collection, analysis and dissemination at EU level, and
works towards better data quality and comparability.
In particular, since 2008, ECDC has been collecting disease
surveillance data from EU Member States on >50 communi-
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cable diseases and conditions using the European Surveillance
System, known as TESSy [4]. After thorough evaluation and
assessment, coordination of the existing dedicated surveillance
networks in Europe was gradually transferred to ECDC [4]. In
total, 16 out of 17 dedicated surveillance networks functioning
in the ﬁeld of public health before establishment of ECDC
were transferred by the end of 2011. During this transfer
process, ECDC formalized the disease-speciﬁc networks of
national experts nominated by Member States, along with the
Coordination Groups for each of the transferred networks,
and ensured representation of all Member States with linkage
to the National Public Health Institutes or equivalent struc-
tures in these networks. The coordination of these EU
surveillance networks fell under different ECDC Disease
Programmes. In addition to the surveillance networks, labo-
ratory networks were established (where they did not exist
before) for the different diseases or groups of diseases. For
these networks, national laboratory experts were nominated
by Member States. Moreover, ECDC established contractual
support to consortia of national reference laboratories. These
laboratory networks have delivered a number of EU-coordi-
nated activities, including technical capacity building, quality
assurance, epidemic intelligence and event response support,
technology assessment, technical guidance and molecular
microbiological surveillance.
The coordination of the three VPD EU surveillance
networks, namely the European Union Invasive Bacterial
Diseases Surveillance System (EU-IBIS), the Diphtheria Sur-
veillance Network (DIPNET), and the European surveillance
network for selected vaccine-preventable diseases (EUVAC),
has been subsequently transferred to ECDC. The former
Invasive Bacterial Infections Surveillance Network (EU-IBIS),
including surveillance of diseases caused by Neisseria meningit-
idis and H. inﬂuenzae, was transferred to ECDC in 2007. In
2010 the enhanced EU surveillance system for invasive diseases
due to Streptococcus pneumoniae was set up and integrated with
the surveillance of diseases caused by N. meningitidis and
H. inﬂuenzae. Currently the Invasive Bacterial Diseases (IBD)
network integrates surveillance of the three invasive bacterial
diseases from an epidemiological and laboratory point of view,
to promote data comparability and high data quality, monitor
the epidemiological trends, as well as the serotype replace-
ment, and strengthen laboratory capacities in Member States.
The activities include annual data collection, analysis, dissem-
ination of relevant scientiﬁc and technical data, promotion of
the harmonization and external quality assurance (EQA) of
laboratory methods and improvement of the laboratory
performance to accurately characterize the isolates of
N. meningitidis, H. inﬂuenzae and S. pneumoniae. The coordina-
tion of the laboratory surveillance activities, mainly EQA
schemes, and training are outsourced to a consortium of
European laboratory experts, coming from national reference
laboratories, led by the University of Wurzburg, Germany (the
Invasive Bacterial Disease Laboratory Network: IBD-Labnet).
Reports on EQA schemes performed to assess the laboratory
capacity of the IBD National Reference Laboratories, are
regularly published on the ECDC website [5–7].
ECDC coordinates a pilot project ‘Assessing the impact of
vaccination with the conjugate vaccines on the epidemiology of
the invasive pneumococcal disease in Europe’ since 2012. The
aim of the project is to set up active surveillance for Invasive
Pneumococcal Disease (IPD) in the EU and European
Economic Area (EEA) to monitor the impact of PCV vaccina-
tion programmes. A network of 12 partner institutions from
nine countries is part of it, coordinated by EpiConcept and
with the creation of 11 surveillance sites. In each of them,
laboratory experts and epidemiologists work closely together
to actively detect and report IPD cases in a timely manner.
Responsibilities of the European Diphtheria Surveillance
Network, EDSN (former DIPNET), including surveillance for
diphtheria caused by toxigenic strains of Corynebacterium
diphtheriae and Corynebacterium ulcerans have been transferred
to ECDC in 2010. The activities of the network are aimed at
integrating epidemiological and laboratory surveillance. The
coordination of the laboratory surveillance activities, mainly
EQA schemes and training, are outsourced to a consortium of
European laboratory experts from national reference labora-
tories, led by the National Public Health Institute of England &
Wales [8].
Finally, EUVAC.NET was a European surveillance network
for measles, mumps, rubella, congenital rubella syndrome,
pertussis and varicella whose responsibilities were transferred
to ECDC in 2011. Currently, EU enhanced surveillance for
measles, mumps, rubella and pertussis is in place at ECDC. Most
of the surveillance data are gathered once a year through a data
call. Measles and rubella data are collected on a monthly basis,
and a monthly bulletin is published on the ECDC website,
containing information on national and European trends, as well
as on outbreaks in the EU for the two diseases [9].
The European Pertussis Laboratory Network (EUpert-
Labnet) was set up in 2011. The coordination of the activities,
mainly EQA schemes, is outsourced to a consortium of
European laboratory experts led by the National Public Health
Institute of Finland [10]. The main outputs of this network so
far are two complementary guidance and protocols on
Bordetella pertussis, the ﬁrst on serological diagnosis of human
infection and the second on the use of RT-PCR for diagnosis of
Bordetella infections [11,12].
In addition to surveillance of diseases, monitoring of other
parameters is of crucial importance for a well-functioning
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immunization system. One of them is vaccination coverage in
the population. The aims of the VENICE project (Vaccine
European New Integrated Collaboration Effort), coordinated
by Istituto Superiore di Sanita in Italy, are to collect and
disseminate information about vaccination, including coverage
data, and to share best practices from EU Member States
through collaboration with a network of national European
‘gatekeepers’—immunization experts [13]. The project stim-
ulates collaboration among EU Member States while acknowl-
edging the heterogeneity in immunization systems. The
VENICE project coordinates, among others, work on the
European Vaccination Coverage Collection System (EVACO),
which is meant to provide ECDC and EU with reliable data on
vaccination coverage in Europe. These data can be used to
assess the effects of vaccination campaigns and to compare
vaccination coverage with disease incidence. As part of a pilot
project, original data on vaccination coverage have been
successfully uploaded and vaccination coverage data have been
transmitted to ECDC electronically. As the next step,
integration of EVACO information into the WHO Centralized
Information System for Infectious Diseases is being explored
[14]. EVACO will be used for a promotion of electronic
immunization information systems (vaccine registries).
The role of ECDC in the area of VPD is not limited to
passive monitoring. According to its founding regulation [15],
the Centre shall provide independent scientiﬁc opinions,
including in the area of immunization. The process of the
delivery of such scientiﬁc advice starts with priority setting
for topics for potential inclusion in the work plan of the
following year. The Centre’s resources are limited, which
necessitates careful selection of the topics on which ECDC
will work in a given year. The ECDC prioritization frame-
work IRIS is used to select the topics of the highest priority
in a transparent way, based on votes from the Centre’s
Advisory Board, which includes public health experts from all
Member States, the European Commission, the WHO,
learned societies and patient organizations [16]. The work
on vaccination guidance usually requires using external
expertise by setting up scientiﬁc expert panels, and the
selection of experts is done using various mechanisms,
including the use of the ECDC expert directory [17]. The
tasks of the external scientiﬁc panels of ECDC are to assist
the Centre in the evaluation of underlying evidence and in
formulating the scientiﬁc advice on a vaccine or vaccines of
interest. By ECDC mandate, scientiﬁc panels are always set
up on an ad hoc basis in response to a need to develop
guidance on a speciﬁc vaccine and their remit and the
duration of their work are stated in advance of their
establishment. They work based on standard operating
procedures and apply the principles of evidence-based
methodology in developing their advice. The resulting guid-
ance is discussed with the ECDC Advisory Forum and is
planned to be progressively discussed publicly on the ECDC
website. Delivered vaccination guidance is usually published
online on the ECDC Web portal [18]. Most recent examples
include the ‘Introduction of HPV vaccines in European Union
countries—an update’ [19]. In addition to long-term vaccina-
tion guidance, ECDC also produces a regular vaccination and
immunization newsletter V&I News, which is a fortnightly
review of scientiﬁc literature and public health news related
to vaccination (it is distributed by email and to subscribe one
needs to send an email to vaccine@ecdc.europa.eu).
Epidemic intelligence is another important part of the VPD
Programme. Messages about VPD outbreaks and measures
taken to control them can be shared through the restricte-
d-access Early Warning and Response system [20]. While
ECDC operates the system, it also maintains a dedicated
internet communication platform called the Epidemic Intelli-
gence Information System (EPIS) [21]. This allows EU public
health institutes and other risk assessment bodies to informally
exchange information regarding current or emerging public
health threats with a potential impact in the EU. This includes
response and monitoring of urgent inquiries regarding early
detection of multinational VPD outbreaks, technical discus-
sions on epidemiology or microbiology of VPD and the sharing
of best practices for their prevention and control. EPIS VPD is
the fourth EPIS platform initiated by ECDC and draws on the
experience with previous EPIS platforms.
If necessary, ECDC initiates and coordinates scientiﬁc
studies in the area of vaccination to answer speciﬁc questions
of public health importance. Examples include the Vaccine
Adverse Events Surveillance and Communication project
(VAESCO) aimed at assessment of vaccine safety signals in
formal epidemiological studies. VAESCO investigators came
from public health institutes, national regulatory agencies and
academic research groups from many EU Member States and
EEA countries. VAESCO used the advantage of conducting
studies on extremely large populations, exceeding in some
cases 40 million people. The network used data linkage of
immunization registries and other health registries containing
medical diagnoses and information on patient characteristics,
as well as ad hoc data collection. Studies performed by
VAESCO included descriptive epidemiological analyses of
background rates of events of interest in vaccine safety in
many populations over several calendar years [22] and also
hypothesis-testing studies [23]. They used both traditional
epidemiological study designs [24] as well more novel designs,
including self-controlled case series [25].
ECDC does not function in a vacuum but operates through
an external VPD Disease Network. Since 2012, the meetings
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of this network have used the format of the ‘Eurovaccine’
conference. The conference brings together international
experts in the ﬁeld of vaccine science and provides a platform
for information and practice exchange among professionals
working in the ﬁelds of regulation, policy, implementation,
monitoring and evaluation of immunization activities in Euro-
pean countries. The agenda includes not only topics related to
the epidemiology of VPD, but also microbiological aspects,
programmatic issues, etc. Some Eurovaccine meetings apply
the ‘virtual conference’ framework with web-based interactive
participation and social media involvement [26].
ECDC also coordinates training activities in the ﬁeld of VPD,
e.g. through the ‘Train the trainers’ course: ‘Epidemiological
aspects of vaccine-preventable diseases’ run by Istituto Superi-
ore di Sanita (ISS) and Agenzia Sanitaria Locale (ASL) in Italy. The
objective is to build capacity to organize, manage and conduct
training courses on epidemiological methods applied to VPD.
Evidence-based communication is an important part of
every public health programme and its effectiveness impacts
strongly on vaccination acceptance [27]. In the area of VPD it
involves risk perception and analysis of behaviours in different
population groups and ECDC projects in this, including
adherents of homeopathy, naturopathy, alternative medicine,
religious/philosophical groups, followers of conspiracy theories
and marginalized groups [28].
One of the overall ECDC priorities over recent years has
been the Centre’s involvement in measles elimination. To
support this initiative ECDC developed several documents and
tools, including an interactive ‘Measles Atlas’ [29], and ‘the
Message’ (a measles and rubella self-assessment generating
tool) [30]. The Measles Atlas provides an overview of the
current and historical measles trends from 1998 to 2012. The
main epidemiological indicators, proposed by WHO in the
measles surveillance guidelines, have been calculated at
national and EU levels to assess how many Member States
meet the WHO threshold for measles elimination (less than
one conﬁrmed case per million population per year) [31].
‘The Message’ is a self-administered, online questionnaire,
which allows the national immunization managers to assess
where their country is on the path to the elimination of
measles, to ﬁnd gaps in programme planning, and to prepare
for the WHO veriﬁcation process. The tool automatically
produces a report, which can be used for further more
detailed assessment and action.
Thereare several ECDCprojects aimedat supportingmeasles
elimination, with a speciﬁc focus on communication and vacci-
nation advocacy. Examples include a vaccine communication
guide ‘Let’s talk about protection’, which has been published
recently [32]. It is a practical tool targeting primary healthcare
providers aimed at supporting them during conversations with
their patients on immunization, with a special focus on MMR
(measles/mumps/rubella). Speciﬁc messages and approaches
have been developed for mothers and grandmothers and for so
called hard-to-reach population groups, e.g. Roma, anthropo-
sophic communities, etc. All messages are evidence-based and
checked with the respective target group members.
Other ECDC disease programmes cover diseases that are
preventable by vaccination. There are strong synergies
between the ECDC VPD Programme and the Inﬂuenza and
other Respiratory Viruses Programme, but also with the
Tuberculosis Programme and the Programme on Sexually
Transmitted Infections, including HIV and blood-borne infec-
tions, which covers hepatitis B, a VPD. Tick-borne encephalitis
and hepatitis A are other examples of VPD that are covered by
other ECDC programmes.
Numerous documents and tools produced by ECDC in the
area of vaccination are posted on the Centre’s Web Portal,
which aspires to be a ‘one stop-shop’ for vaccine-related
practical information on the Web. One important sub-site to
visit is ECDC ‘Vaccine Scheduler’ [33] with information on
vaccination schedules in the EU/EEA countries collected by
ECDC national focal points. It allows for comparison of
schedules between two countries and among diseases for all or
a selection of countries and vaccines.
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